Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
0.9843
Dollar change
-0.0857
Percentage change
-8.01
%
IndexRUT P/E- EPS (ttm)-2.93 Insider Own7.02% Shs Outstand98.77M Perf Week-22.50%
Market Cap97.22M Forward P/E- EPS next Y-0.44 Insider Trans0.73% Shs Float91.83M Perf Month-62.72%
Income-284.23M PEG- EPS next Q-0.42 Inst Own71.27% Short Float5.65% Perf Quarter1.44%
Sales147.75M P/S0.66 EPS this Y54.53% Inst Trans2.89% Short Ratio1.85 Perf Half Y94.10%
Book/sh-2.07 P/B- EPS next Y67.20% ROA-55.00% Short Interest5.19M Perf Year-94.17%
Cash/sh2.39 P/C0.41 EPS next 5Y- ROE-42790.17% 52W Range0.33 - 20.28 Perf YTD11.06%
Dividend Est.- P/FCF- EPS past 5Y-23.23% ROI- 52W High-95.15% Beta0.87
Dividend TTM- Quick Ratio1.33 Sales past 5Y-2.51% Gross Margin87.24% 52W Low195.32% ATR (14)0.21
Dividend Ex-Date- Current Ratio1.52 EPS Y/Y TTM6.75% Oper. Margin-182.20% RSI (14)26.20 Volatility14.31% 16.00%
Employees486 Debt/Eq- Sales Y/Y TTM4.99% Profit Margin-192.37% Recom4.00 Target Price1.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q18.88% Payout- Rel Volume0.77 Prev Close1.07
Sales Surprise-30.24% EPS Surprise-34.12% Sales Q/Q-21.03% EarningsFeb 26 AMC Avg Volume2.81M Price0.98
SMA20-38.86% SMA50-47.69% SMA200-23.03% Trades Volume2,164,655 Change-8.01%
Date Action Analyst Rating Change Price Target Change
Aug-08-23Downgrade BofA Securities Neutral → Underperform $4 → $2
Jun-26-23Downgrade William Blair Outperform → Mkt Perform
Jun-26-23Downgrade Stifel Buy → Hold
Jun-26-23Downgrade Raymond James Outperform → Mkt Perform
Jun-26-23Downgrade BofA Securities Buy → Neutral
Jun-02-23Upgrade Stifel Hold → Buy $23 → $32
Jan-31-23Upgrade William Blair Mkt Perform → Outperform
Jan-26-23Upgrade Raymond James Mkt Perform → Outperform $35
Jan-05-23Upgrade BofA Securities Neutral → Buy $18 → $27
Sep-22-21Downgrade Goldman Neutral → Sell $16 → $11
Apr-24-24 04:02PM
Apr-03-24 09:32AM
Apr-02-24 05:46PM
Mar-26-24 07:00AM
Mar-20-24 03:45PM
07:00AM Loading…
Mar-11-24 07:00AM
Feb-29-24 08:09AM
Feb-27-24 09:59AM
Feb-26-24 05:50PM
04:40PM
04:34PM
04:15PM
04:06PM
04:05PM
Feb-20-24 07:00AM
07:00AM Loading…
Feb-05-24 07:00AM
Jan-25-24 07:00AM
Dec-09-23 05:02PM
Nov-07-23 11:01AM
10:01AM
Nov-06-23 05:33PM
05:30PM
04:10PM
04:01PM
Oct-23-23 07:00AM
Aug-31-23 10:15AM
Aug-30-23 11:09AM
Aug-29-23 06:00PM
04:15PM
Aug-16-23 09:35AM
09:14AM Loading…
Aug-09-23 09:14AM
Aug-08-23 10:08AM
08:59AM
Aug-07-23 07:30PM
05:40PM
04:26PM
04:01PM
Jul-31-23 09:00AM
Jul-25-23 10:49AM
07:00AM
Jul-24-23 07:00AM
Jul-21-23 07:17AM
Jul-19-23 10:50AM
Jul-14-23 09:55AM
Jul-11-23 09:35AM
Jul-01-23 08:46AM
Jun-27-23 12:45PM
Jun-26-23 04:04PM
11:34AM
07:22AM
07:11AM
07:04AM
Jun-08-23 01:03PM
Jun-07-23 04:03PM
11:47AM
07:02AM
06:55AM
Jun-06-23 04:01PM
02:06PM
May-18-23 07:30AM
May-09-23 10:22AM
May-08-23 05:15PM
04:12PM
04:01PM
04:00PM
May-05-23 01:19PM
07:37AM
07:30AM
May-03-23 03:43AM
May-01-23 07:00AM
Apr-24-23 07:00AM
Apr-03-23 07:00AM
Mar-24-23 10:21AM
Mar-11-23 03:27AM
Feb-28-23 02:43PM
Feb-27-23 05:25PM
04:01PM
07:00AM
Feb-23-23 11:33AM
07:46AM
Feb-22-23 10:00AM
Feb-20-23 10:00AM
Feb-17-23 07:00AM
Feb-02-23 07:00AM
Jan-16-23 09:34AM
Nov-28-22 07:00AM
Nov-09-22 05:15AM
Nov-07-22 05:45PM
04:01PM
04:00PM
Nov-01-22 07:00AM
Oct-31-22 10:00AM
Oct-24-22 07:00AM
Oct-15-22 09:59AM
Sep-23-22 07:30AM
Aug-26-22 07:00AM
Aug-09-22 06:30AM
Aug-08-22 05:35PM
04:01PM
Jul-25-22 07:00AM
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wettig ThaneCEOMar 07 '24Buy1.9150,00095,470470,178Mar 11 07:06 PM
Henderson Jeffrey WilliamDirectorSep 01 '23Sale1.032,0002,06028,866Sep 06 08:54 PM
Henderson Jeffrey WilliamDirectorAug 04 '23Sale1.912,0003,82030,866Aug 08 07:10 PM
Henderson Jeffrey WilliamDirectorJul 11 '23Sale2.692,0005,38032,866Jul 13 08:28 PM
Conterno Enrique AChief Executive OfficerJul 07 '23Sale2.801,8805,264374,722Jul 10 07:36 PM
Wettig ThaneChief Commercial OfficerJun 23 '23Sale16.5379113,075108,261Jun 26 04:27 PM
Chung ChristineSVP, China OperationsJun 14 '23Sale16.796,250104,925236,327Jun 15 08:17 PM
Chung ChristineSVP, China OperationsJun 13 '23Sale17.606,250110,000242,577Jun 15 08:17 PM
Blaug SuzanneDirectorJun 09 '23Sale17.208,520146,57129,594Jun 09 07:54 PM
EDWARDS JEFFREY LDirectorJun 09 '23Sale17.197,889135,62233,977Jun 09 07:53 PM
Brennan AoifeDirectorJun 09 '23Sale17.194,73381,36727,947Jun 09 07:55 PM
Cravatt BenjaminDirectorJun 09 '23Sale17.173,94467,71728,736Jun 09 07:56 PM
Ho MaykinDirectorJun 08 '23Sale17.448,520148,59131,501Jun 09 07:54 PM
Henderson Jeffrey WilliamDirectorJun 08 '23Sale17.467,000122,18534,866Jun 09 07:52 PM
Conterno Enrique AChief Executive OfficerJun 07 '23Sale17.048,897151,583376,602Jun 09 07:10 PM
Schoeneck James ADirectorJun 07 '23Sale18.037,100127,98773,722Jun 09 07:51 PM
Chung ChristineSVP, China OperationsJun 07 '23Sale17.043,63361,894248,827Jun 09 07:38 PM
Eisner MarkEVP, Chief Medical OfficerJun 07 '23Sale17.042,04234,792162,862Jun 09 07:12 PM
Graham JuanChief Financial OfficerJun 07 '23Sale16.991,78530,32071,083Jun 09 07:39 PM
Wettig ThaneChief Commercial OfficerJun 07 '23Sale17.041,75829,951111,395Jun 09 07:39 PM
Eisner MarkEVP, Chief Medical OfficerJun 02 '23Sale18.831,09020,525164,904Jun 05 04:22 PM